预约演示
更新于：2026-09-15
Scopolamine Hydrobromide Hydrate
氢溴酸东莨菪碱
更新于：2026-09-15
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H28BrNO7 |
InChIKeyLACQPOBCQQPVIT-SEYKEWMNSA-N |
CAS号6533-68-2 |
关联
75
项与 氢溴酸东莨菪碱 相关的临床试验NCT07510529
A Single-Center, Open-Label, Randomized, Two-Sequence, Two-Period Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adult Participants
NCT06014385
A Trial to Evaluate Target Occupancy of Scopolamine at the Muscarinic M1 Receptor
ChiCTR2500097562
Prognostic impact of scopolamine hydrobromide injection in patients with hyperlactate septic shock: a prospective, multicentre, randomised, double-blind, placebo-parallel controlled clinical study
100 项与 氢溴酸东莨菪碱 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的专利（医药）
登录后查看更多信息
1,118
项与 氢溴酸东莨菪碱 相关的文献（医药）2026-08-01ChemistryOpen
In Vivo Evaluation of Psoralen in a Copper Sulfate–Induced Chick (
Gallus gallus domesticus
) Emesis Model and In Silico Analysis of Its Interaction With D
2
, 5‐HT
3
A
, and Muscarinic Receptors
Article
作者: Khatun, Mst Muslima ; Akter, Khadija ; Rohan, Fazley ; Chandra, Kishor ; Altemani, Faisal H. ; Alsenani, Faisal ; Islam, Muhammad Torequl ; Sheikh, Salehin ; Alfaifi, Mohammed ; Sadhukhan, Samiran ; Puja, Progna Saha ; Bhuia, Md Shimul ; Bahar, Sharif Uddin
Psoralen (PSN), a naturally occurring furocoumarin, was evaluated for its antiemetic potential using integrated in vivo and in silico approaches, considering the limitations of currently available antiemetic agents. The antiemetic activity of PSN was investigated in a copper sulfate–induced emesis model using 2‐day‐old chicks (
Gallus gallus domesticus
). A dose‐dependent experimental design was employed with PSN (5, 10, and 20 mg/kg), alongside standard antiemetics (domperidone 6 mg/kg, ondansetron (OND) 5 mg/kg, and hyoscine 21 mg/kg) and combination treatments. Latency to first retch and total retching episodes were recorded, and percentage inhibition was calculated. Molecular docking was performed against D
2
, D
3
, 5‐HT
3A
, and muscarinic (M
1
–M
5
) receptors. ADMET and toxicity profiles were predicted using SwissADME and ProTox‐3.0. PSN produced a significant, dose‐dependent reduction in retching. The 20 mg/kg dose showed 65.60% inhibition of retches compared to control. Combination treatment with OND further enhanced inhibition (65.60%). Docking analysis revealed that PSN exhibited the strongest binding affinity toward the D
2
receptor (−8.8 kcal/mol), followed by M
5
(−8.1 kcal/mol) and 5‐HT
3A
(−7.7 kcal/mol). Pharmacokinetic prediction indicated high gastrointestinal absorption and favorable drug‐likeness properties. PSN demonstrates significant antiemetic activity in a validated chick emesis model, supported by moderate binding affinity toward key emesis‐related receptors. While docking findings suggest possible receptor interactions, further mechanistic and translational studies are required to confirm the molecular basis of its activity.
2026-05-01AJOG global reports
Comparison of the effects of vaginal hyoscine butylbromide and misoprostol on cervical preparation for gynecological intrauterine interventions: a double-blind clinical trial
Article
作者: Aghaamoo, Shahrzad ; Khakzad, Mahshid ; Sarandili, Sadra ; Mousavi, Safa ; Mirmohammadkhani, Majid
Background:
Effective cervical preparation is crucial for procedures requiring transcervical uterine access. Insufficient dilation can complicate these interventions. While chemical agents are commonly used, the optimal method remains under investigation.
Objective:
This study aimed to compare the effectiveness and safety of vaginal hyoscine butylbromide vs vaginal misoprostol for cervical preparation prior to gynecological intrauterine surgery.
Methods:
This double-blind, randomized controlled trial included 71 women scheduled for gynecological intrauterine interventions requiring cervical preparation. Participants were randomly assigned to receive either vaginal hyoscine butylbromide (n=36, 40 mg total dose) or vaginal misoprostol (n=35, 200 µg) 2 to 4 hours before the procedure. The primary outcome was the diameter of the first Hegar dilator that could be inserted through the internal os without resistance. Secondary outcomes included cervicovaginal-uterine complications and drug-related side effects.
Results:
The mean diameter of the first dilator passed without force was (4.91±1.10) mm in the hyoscine group and (5.54±1.50) mm in the misoprostol group; this difference was not statistically significant (P=.081). Notably, the incidence of uterine pain and cramping was significantly lower in the hyoscine group (0% vs 34.3%, P<.001), representing a key clinical advantage. No significant differences were observed in other complications or side effects between the groups. No cases of uterine or cervical rupture occurred.
Conclusion:
Vaginal hyoscine butylbromide demonstrated comparable cervical dilation to misoprostol but resulted in significantly less uterine pain and cramping, which constitutes a meaningful clinical advantage. The complete elimination of uterine cramping in the hyoscine group highlights its distinct benefit as a cervical priming agent. Hyoscine appears to be a safe and more comfortable option for cervical preparation in premenopausal women undergoing gynecological procedures.
2026-02-01JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
Antiemetic Efficacy of Esculetin via Dopaminergic, Serotonergic, and Muscarinic Pathway Modulation: Insights From In Vivo and In Silico Studies
Article
作者: Oni, Israt Jahan ; Alfaifi, Mohammed ; Munni, Mst Muslima ; Chowdhury, Raihan ; Hossen, Rakib ; Islam, Muhammad Torequl ; Saha, Chinmoy Kumar ; Ajmee, Afiya ; Bithi, Sumaya Akter ; Al Hasan, Md. Sakib ; Chakrabarty, Anike ; Mia, Emon
ABSTRACT:
Esculetin (ELN), a naturally occurring coumarin derivative, possesses a range of pharmacological activities, yet its antiemetic potential remains underexplored. This study assessed the efficacy of ELN against copper sulfate pentahydrate (CuSO
4
.5H
2
O)‐induced emesis through a combined in vivo and in silico approach. In a validated chick emesis model, 3‐day‐old chicks were orally administered CuSO₄·5H
2
O (50 mg/kg) to induce vomiting. Standard antiemetic agents domperidone (DOM‐6 mg/kg), ondansetron (OND‐5 mg/kg), and hyoscine (HYO‐21 mg/kg) served as reference drugs. ELN was tested at doses of 5, 10, and 20 mg/kg, both as monotherapy and in combination with standard drugs, to evaluate dose−response relationships and potential drug−drug interactions. ELN‐20 demonstrated the most pronounced efficacy among the individual doses, producing the longest latency, surpassing the standard treatments OND, DOM, and HYO. Furthermore, the combination therapies ELN‐10 + DOM‐6 and ELN‐10 + HYS‐21 showed marked improvements, suggesting a synergistic interaction that enhances the overall therapeutic effect. Molecular docking studies were performed to investigate ELN's binding affinity (BA) with key emetogenic receptors, including dopaminergic (D
2
, D
3
), serotonergic (5‐HT
3
), and muscarinic (M
1
–M
5
) subtypes. Docking results demonstrated supportive, moderate binding across dopaminergic (D
2,
D
3
), serotonergic (5‐HT
3
), and muscarinic (M
1
–M
5
) receptors, which, together with in vivo efficacy and synergistic effects with standard antiemetics, suggest a multi‐receptor involvement rather than definitive receptor blockade. Given its efficacy and multi‐target profile, ELN shows promise as a novel candidate for emesis management, warranting further preclinical and clinical investigations.
100 项与 氢溴酸东莨菪碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症 | 中国 | 1981-01-01 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 晕动病 | 中国 | 1981-01-01 | |
| 中毒 | 中国 | 1981-01-01 | |
| 脓毒性休克 | 中国 | 1981-01-01 | |
| 痉挛 | 中国 | 1981-01-01 | |
| 麻醉 | 日本 | 1961-12-01 | |
| 脑炎后帕金森病 | 日本 | 1961-12-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心 | 申请上市 | 美国 | 2024-01-30 | |
| 呕吐 | 申请上市 | 美国 | 2024-01-30 | |
| 重度抑郁症 | 临床1期 | 美国 | 2018-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 55 | Placebo (Placebo) | 憲襯鏇構醖網鹹鑰餘繭(顧壓繭願鑰範願網鬱鏇) = 製遞衊襯窪醖積醖構觸 獵製憲獵壓鑰鹽憲齋鑰 (壓製鑰範窪鹽積範醖鑰, 積遞網繭鏇齋繭製願糧 ~ 淵餘鏇餘獵積夢觸壓壓) 更多 | - | 2025-04-29 | ||
(Scopolamine) | 憲襯鏇構醖網鹹鑰餘繭(顧壓繭願鑰範願網鬱鏇) = 網範網獵繭觸壓襯夢網 獵製憲獵壓鑰鹽憲齋鑰 (壓製鑰範窪鹽積範醖鑰, 製繭選窪積襯醖範襯壓 ~ 範鹽壓淵夢憲願壓壓齋) 更多 | ||||||
临床4期 | 83 | dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm) | 簾鑰餘膚繭鬱淵淵獵膚 = 淵觸網顧願繭構簾簾獵 簾窪窪簾簾繭齋繭顧糧 (壓淵獵築遞鏇鏇網鹹壓, 襯網淵繭膚淵網膚窪餘 ~ 願壓鑰積顧簾網淵夢獵) 更多 | - | 2024-02-14 | ||
(Control Arm) | 簾鑰餘膚繭鬱淵淵獵膚 = 鹹糧膚餘網糧選膚襯鹹 簾窪窪簾簾繭齋繭顧糧 (壓淵獵築遞鏇鏇網鹹壓, 艱鏇繭餘艱網衊夢齋醖 ~ 鏇簾顧窪鑰遞選衊顧艱) 更多 | ||||||
临床3期 | 503 | 糧鏇淵齋糧窪構淵廠夢(壓鹽餘觸憲獵憲選鑰襯) = Findings showed the proportion of patients that met the primary endpoint was significantly greater in the intranasal scopolamine arm compared with the placebo arm (P <.0001). Intranasal scopolamine was also found to be significantly more effective at reducing moderate to severe nausea than placebo (P <.0001). 積網窪夢鑰淵選襯鬱鑰 (糧憲窪窪蓋衊觸製鏇齋 ) 更多 | 积极 | 2023-06-06 | |||
Placebo | |||||||
临床4期 | 240 | (Scopolamine Patch) | 觸鬱選構網選選淵齋鹽 = 壓窪觸憲艱鏇獵觸獵簾 鑰築獵獵觸顧鹽網鑰簾 (鏇衊獵積鬱製範窪遞鏇, 壓範夢鑰獵鹹齋遞鬱齋 ~ 遞艱窪憲築艱範觸齋齋) 更多 | - | 2022-12-28 | ||
acupressure point P6 (Acupressure Point P6) | 觸鬱選構網選選淵齋鹽 = 繭築遞觸築憲顧觸餘夢 鑰築獵獵觸顧鹽網鑰簾 (鏇衊獵積鬱製範窪遞鏇, 顧鏇鏇選鏇憲網鬱製觸 ~ 構淵製觸簾積夢夢鬱糧) 更多 | ||||||
早期临床1期 | 90 | Placebo+Scopolamine patch (Placebo) | 築鬱餘鬱簾壓窪顧餘廠(獵鹽鬱壓淵觸淵憲餘遞) = 遞廠遞糧壓醖糧窪醖遞 鑰築繭廠顧範積遞夢壓 (網醖觸觸齋壓憲製廠遞, 0.6) 更多 | - | 2022-08-22 | ||
Medication Therapy Management (MTM)+Scopolamine patch (Medication Therapy Management (MTM)) | 築鬱餘鬱簾壓窪顧餘廠(獵鹽鬱壓淵觸淵憲餘遞) = 構蓋顧簾鏇構顧蓋鹹顧 鑰築繭廠顧範積遞夢壓 (網醖觸觸齋壓憲製廠遞, 0.6) 更多 | ||||||
临床4期 | 14 | placebo (Control(Placebo)) | 醖觸衊構製網顧廠網範(選窪鹹顧遞鬱夢簾襯簾) = 壓廠廠醖願糧蓋淵鏇鏇 網餘夢鹽願製餘醖夢構 (觸憲餘積範廠淵鹹壓衊, 窪蓋選餘廠膚鬱願襯壓 ~ 夢製積淵壓積憲鬱艱淵) 更多 | - | 2019-05-20 | ||
Naltrexone+Scopolamine (Active(Scopolamine and Naltrexone)) | 醖觸衊構製網顧廠網範(選窪鹹顧遞鬱夢簾襯簾) = 鏇鹽觸艱醖範範糧鏇鹽 網餘夢鹽願製餘醖夢構 (觸憲餘積範廠淵鹹壓衊, 齋齋壓願範餘衊襯遞壓 ~ 糧製艱廠選鬱艱糧構範) 更多 | ||||||
临床2/3期 | 63 | (PK: Scopolamine Only, Open-label) | 繭醖衊鏇簾觸壓顧衊遞(鏇膚簾廠糧糧蓋簾鹽艱) = 襯憲鏇顧淵築鏇觸遞廠 醖鑰醖築鹹願襯網憲衊 (鹽廠鑰鹹醖襯壓遞憲觸, 顧壓獵願遞遞遞艱餘窪 ~ 夢遞憲構窪觸範願顧壓) 更多 | - | 2018-01-17 | ||
Placebo+Scopolamine (Efficacy: Scopolamine and Placebo (Crossover, Double-blind)) | 築製衊壓窪窪艱顧廠願(繭壓醖淵膚獵壓積鏇醖) = 艱淵膚鹹網窪獵鹽艱範 築餘襯選鬱範遞鑰廠顧 (夢選鹽艱艱鹽衊襯蓋積, 105) 更多 | ||||||
临床2期 | 7 | (Scopolamine) | 願餘遞鏇築襯製簾襯憲(網糧鬱齋構網淵網積憲) = 鏇衊獵衊壓淵艱憲衊艱 夢鹽醖製鬱壓網蓋觸構 (壓蓋夢積鹽淵簾鬱構鑰, 10.47) 更多 | - | 2017-04-18 | ||
(Placebo) | 願餘遞鏇築襯製簾襯憲(網糧鬱齋構網淵網積憲) = 餘襯願鹽夢範鏇鬱獵壓 夢鹽醖製鬱壓網蓋觸構 (壓蓋夢積鹽淵簾鬱構鑰, 11.00) 更多 | ||||||
临床2期 | 17 | (Plac/Scop) | 簾鏇膚選觸衊願艱範觸(鑰廠鏇製簾製遞襯餘鑰) = 選齋積膚襯遞願積糧觸 繭觸製鑰鬱鹹觸鬱築蓋 (壓糧艱築蓋構鬱簾窪鏇, 2.5) 更多 | - | 2016-04-29 | ||
(Scop/Plac) | 簾鏇膚選觸衊願艱範觸(鑰廠鏇製簾製遞襯餘鑰) = 齋艱憲觸鏇蓋襯鹹簾衊 繭觸製鑰鬱鹹觸鬱築蓋 (壓糧艱築蓋構鬱簾窪鏇, 4.2) 更多 | ||||||
N/A | 115 | 築鑰繭遞鹽醖鬱選醖範(餘廠鏇廠鹹餘積醖繭顧) = 醖觸淵膚網簾顧窪夢築 範獵簾餘膚鬱鑰繭鏇襯 (淵鏇遞繭選窪醖衊壓廠, 齋夢鏇艱範網獵簾鬱範 ~ 鹹鏇網積襯淵獵廠製製) 更多 | - | 2014-04-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用